Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis

Overview

Journal P T

Specialty Pharmacology

Date 2015 Aug 4

PMID 26236139

Citations 222

Authors

George DeMaagd

Ashok Philip

Affiliations

Soon will be listed here.

Abstract

This article-the first of a five-part series-discusses possible causes, symptoms, diagnosis, and goals for treatment of Parkinson's disease. Identifying diseases that have similar presentations is an important component of the diagnostic process.

Citing Articles

Concealment of Parkinsons disease prevalence and impact on health and quality of life.

Naamneh-Abuelhija B, Kafri M, Kestenbaum M, Giveon S, Kamah S, Shved S Sci Rep. 2025; 15(1):7551.

PMID: 40038366 PMC: 11880477. DOI: 10.1038/s41598-025-91579-8.

Deep Learning-Based Diagnostic Model for Parkinson's Disease Using Handwritten Spiral and Wave Images.

Shastry K Curr Med Sci. 2025; .

PMID: 40029495 DOI: 10.1007/s11596-025-00017-3.

Ferroptosis role in complexity of cell death: unrevealing mechanisms in Parkinson's disease and therapeutic approaches.

Awasthi A, Maparu K, Singh S Inflammopharmacology. 2025; .

PMID: 39998712 DOI: 10.1007/s10787-025-01672-7.

Transcutaneous vagus nerve stimulation for Parkinson's disease: a systematic review and meta-analysis.

Shan J, Li Z, Ji M, Zhang M, Zhang C, Zhu Y Front Aging Neurosci. 2025; 16:1498176.

PMID: 39877075 PMC: 11772336. DOI: 10.3389/fnagi.2024.1498176.

A Scoping Review of Educational and Training Interventions on Parkinson's Disease for Staff in Care Home Settings.

Finlay S, Anderson T, Henderson E, Brown Wilson C, Stark P, Carter G Nurs Rep. 2025; 15(1).

PMID: 39852642 PMC: 11768021. DOI: 10.3390/nursrep15010020.

References

Sozio P, Cerasa L, Abbadessa A, Di Stefano A . Designing prodrugs for the treatment of Parkinson's disease. Expert Opin Drug Discov. 2012; 7(5):385-406. DOI: 10.1517/17460441.2012.677025. View

Lee C, Kim M, Lee H, Jang J, Lee S, Kwon D . The interrelationship between non-motor symptoms in Atypical Parkinsonism. J Neurol Sci. 2013; 327(1-2):15-21. DOI: 10.1016/j.jns.2013.01.034. View

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

Marras C, Goldman S . Genetics meets environment: evaluating gene-environment interactions in neurologic diseases. Semin Neurol. 2012; 31(5):553-61. DOI: 10.1055/s-0031-1299793. View

Politis M, Wu K, Molloy S, Bain P, Chaudhuri K, Piccini P . Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010; 25(11):1646-51. DOI: 10.1002/mds.23135. View

van der Marck M, Bloem B, Borm G, Overeem S, Munneke M, Guttman M . Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord. 2012; 28(5):605-11. DOI: 10.1002/mds.25194. View

Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F . Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012; 69(11):1445-52. DOI: 10.1001/archneurol.2012.1654. View

Uitti R . Treatment of Parkinson's disease: focus on quality of life issues. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S34-6. DOI: 10.1016/S1353-8020(11)70013-X. View

Postuma R, Aarsland D, Barone P, Burn D, Hawkes C, Oertel W . Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord. 2012; 27(5):617-26. DOI: 10.1002/mds.24996. View

10.

Mendonca D, Jog M . Tasks of attention augment rigidity in mild Parkinson disease. Can J Neurol Sci. 2008; 35(4):501-5. View

11.

Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman N . Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol. 2012; 175(11):1200-7. PMC: 3370885. DOI: 10.1093/aje/kwr451. View

12.

Cardoso F . Difficult diagnoses in hyperkinetic disorders - a focused review. Front Neurol. 2012; 3:151. PMC: 3482700. DOI: 10.3389/fneur.2012.00151. View

13.

Baumann C . Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S90-2. DOI: 10.1016/S1353-8020(11)70029-3. View

14.

Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W . Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66(7):968-75. DOI: 10.1212/01.wnl.0000215437.80053.d0. View

15.

Miller D, Caroff S, Davis S, Rosenheck R, McEvoy J, Saltz B . Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008; 193(4):279-88. PMC: 2801816. DOI: 10.1192/bjp.bp.108.050088. View

16.

Martinez T, Greenamyre J . Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal. 2011; 16(9):920-34. PMC: 3292753. DOI: 10.1089/ars.2011.4033. View

17.

Pfeiffer R . Autonomic dysfunction in Parkinson's disease. Expert Rev Neurother. 2012; 12(6):697-706. DOI: 10.1586/ern.12.17. View

18.

Van der Merwe C, Haylett W, Harvey J, Lombard D, Bardien S, Carr J . Factors influencing the development of early- or late-onset Parkinson's disease in a cohort of South African patients. S Afr Med J. 2012; 102(11 Pt 1):848-51. DOI: 10.7196/samj.5879. View

19.

Kim Y, Joh T . Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med. 2006; 38(4):333-47. DOI: 10.1038/emm.2006.40. View

20.

Castro Jimenez M, Vingerhoets F . Tremor revisited: treatment of PD tremor. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S93-5. DOI: 10.1016/S1353-8020(11)70030-X. View